openPR Logo
Press release

Subcutaneous Biologics Market Exclusive Analysis by Leading Key Players: Amgen, Inc., Eisai, Inc., AbbVie, Inc., Pfizer Inc, Genentech Inc., Biogen Idec, F. Hoffmann-La Roche AG,

05-27-2019 11:12 AM CET | Health & Medicine

Press release from: Coherent Market Insights

Subcutaneous Biologics

Subcutaneous Biologics

Biologic, also known as biopharmaceutical, is a complex medicinal product manufactured by a biological process. Examples of biologics include blood and plasma derived products, vaccines, somatic cells and body proteins. Biologics market refers to a multibillion dollar opportunity that is expanding globally at an impressive growth rate. Most biologic products are given intravenously. However, in the past few years, a number of biologics have been developed that are given subcutaneously. The subcutaneous route of administration offers significant advantages over intravenous administration such as ease of drug administration, does not require skilled personnel for drug administration, enables at-home drug delivery and thus reduces patient time at healthcare facilities, reduced medicine cost and increased therapy compliance.

Request Sample of Research Report @ www.coherentmarketinsights.com/insight/request-sample/74

In terms of geography, the global market for subcutaneous biologics is segmented into four major regions, namely, North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW). There is huge healthcare spending in countries such as United States and Canada, and high prevalence of diseases such as rheumatoid arthritis and breast cancer. The Centers for Disease Control and Prevention (CDC) estimate that the current prevalence of rheumatoid arthritis (nearly 50 million Americans in 2012) will increase to 78 million by 2040. The disease also affects nearly 300,000 children in the U.S. according to RheumatoidArthritis.org. In the European region, EU-5 countries (Germany, France, United Kingdom, Italy and Spain) are the most potential market owing well established economy of these regions.

Owing to aforementioned factors, the subcutaneous route of administration has gained enormous traction in recent years. Subcutaneous route of drug administration are highly effective in administering biologics such as vaccines, proteins, peptides, antibodies and other large and complex molecules. The global market for subcutaneous biologics will be expanding under the influence of factors such as: Advantages over other routes of administration, Increasing trend of self-medication, Introduction of innovative drug delivery devices such as auto-injectors and prefilled syringes, Growing incidence and prevalence of rheumatoid arthritis and breast cancer, Growth in the biosimilars market,.

For More Information On This Report, Please Visit @ https://www.coherentmarketinsights.com/ongoing-insight/subcutaneous-biologics-market-74

Humira (Adalimumab), MabThera/Rituxan (Rituximab), Zytux (Rituximab), Stelara (ustekinumab), Enbrel (Etanercept)., Neulasta (filgrastim), ORENCIA (abatacept), RoACTEMRA (tocilizumab) and Herceptin (Trastuzumab) are among the major commercially available biologics that are administered through subcutaneous route. F. Hoffmann-La Roche AG announced the European Commission (EU) approval of its subcutaneous formulation of RoACTEMRA (tocilizumab) in April 2014. Amgen launched Neulasta delivery kit in 2015 to automate the delivery of drug and preventing infection in cancer patients.

Some of the major companies operating in the global subcutaneous biologics market include Genentech Inc., Biogen Idec, F. Hoffmann-La Roche AG, Amgen, Inc., Eisai, Inc., AbbVie, Inc., Pfizer Ltd., Takeda Pharmaceutical Company Ltd. and Bristol-Myers Squibb.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Subcutaneous Biologics Market Exclusive Analysis by Leading Key Players: Amgen, Inc., Eisai, Inc., AbbVie, Inc., Pfizer Inc, Genentech Inc., Biogen Idec, F. Hoffmann-La Roche AG, here

News-ID: 1754130 • Views: 387

More Releases from Coherent Market Insights

Frozen Pastries Market, By Product Type (Viennoiserie Products (Plain & Filled C …
Frozen Pastries Market 2017-2027 Frozen pastries are confectionery products that undergo refrigeration before preparation. They have longer shelf-life with a rich source of nutrition and are also available in different flavors. Honey is a key ingredient that is used in frozen pastry as it helps in extending the shelf-life of the pastries. They are gaining more popularity among the population due to expanding retail channel especially online stores that enable easy
Cap Applicator Market, By Machine Type (Automatic Capping Machine, Semi-automati …
Cap Applicators Market 2017-2027 A cap applicator is closing equipment that is used to seal different types of packages such as bottles and other containers. Different cap applicators are available in the market for different closures with different designs and sizes. They are mainly used to seal bottles filled with dairy or liquid products. The capping equipment can be classified into three categories which include, semi-automatic capping machines, automatic capping machines,
Erectile Dysfunction Devices Market 2020 Inclinations - by Meda Pharmaceuticals, …
Erectile dysfunction (ED) also known as impotence, is the inability to get an erection during sexual intercourse. It is a common medical condition in men. Though less common among the younger age group, erectile dysfunction affects 5%-10% of men under 40 years of age. A recent study published in the Journal of Sexual Medicine revealed that one in four patients who sought medical help for erectile dysfunction are under the
Diabetes Nutrition Market Outlook to 2026: Emerging Trends, Highlights and Chall …
Diabetes Nutrition Market Research Report 2020, is mostly driven by the improved taking on of Diabetes Nutrition across small and medium-sized enterprises. Worldwide Diabetes Nutrition Market quantifying the talk on those players at the interval. The report figures the limits and strong points of the players. To begin with the Diabetes Nutrition Market report which covers market characteristics, industry structure and comitative landscape, the problems, desire concepts, along with business

All 5 Releases


More Releases for Subcutaneous

Subcutaneous Injector Sales Market Report 2017
Subcutaneous Injector market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Browse the full report with a table of contents : https://www.reportsandmarkets.com/reports/global-subcutaneous-injector-sales-market-report-2017-1701051 Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Subcutaneous Injector for
US$ 9 Bn Opportunity in Global Subcutaneous Immunoglobulin Market
The global subcutaneous immunoglobulin market is projected to grow at double-digit CAGR through 2024. Demand for subcutaneous immunoglobulin products is influenced by increasing focus on treating primary immunodeficiency diseases. The healthcare infrastructure in many emerging countries has gained center stage owing to concerted efforts on part of governments. On account of these factors, the global subcutaneous immunoglobulin market is expected to reach nearly US$ 9 bn by 2024. These insights
Unmet Need Remains for Subcutaneous Sustained Release Injectables
(Amherst, NH) - As patients live longer and the prevalence and incidence of chronic ailments increase across the general population, drug developers and their delivery device partners are adapting to address what will become a significant market opportunity. Chronic conditions require drug administration over long periods of time, placing a greater emphasis on self-administration and reduced dosing frequency. With the shift away from caregiver interaction, drug safety and compliance/adherence
Global Subcutaneous Immunoglobulin Market | MarketResearchReports.biz
Latest industry research report on: Global Subcutaneous Immunoglobulin Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts Global Subcutaneous Immunoglobulin Market: Overview Primary humoral immunodeficiency or primary immune deficiency diseases (PIDD) is a group of disorders in which the immune system of an individual does not function properly. In PIDD patients, the number of antibodies produced in the body is not sufficient, or the ones produced are
Subcutaneous Immunoglobulin Market Research Report : Forecast up to 2024
Key companies in The Global Subcutaneous Immunoglobulin Market include Grifols S.A., CSL Behring LLC, Shire Plc., Biotest AG, Kedrion S.p.A., Octapharma AG, Baxalta Incorporated, and Talecris Biotherapeutics, Inc. The global subcutaneous immunoglobulin market is likely to present an opportunity-filled landscape for new players in the coming years, while steady expansion efforts are likely to help existing market players consolidate their position in the subcutaneous immunoglobulin market. According to Transparency Market Research
Subcutaneous Immunoglobulin Market Demand and Growth Upto 2024
Immunoglobulin, commonly known as an antibody, is a Y-shaped protein manufactured primarily by plasma cells. Immunoglobulin is utilized by the immune system to counterbalance pathogens. Subcutaneous injections are administered as vaccines and medications including insulin and immunoglobulin. The process of administering immunoglobulin is known as immunoglobulin therapy. When immunoglobulin therapy is applied below the dermis and epidermis, or cutis, it is known as subcutaneous immunoglobulin. Subcutaneous therapy is useful as